Abstract
A quantitative structure-activity relationship study has been made on some pyranyl hydroxamic acid analogs acting as matrix metalloproteinase (MMP) inhibitors. The inhibition potencies of two different series of compounds against two MMP enzymes (MMP-1 and MMP-13) have been analyzed and found to be well correlated with hydrophobic and some indicator parameters of the substituents. In both the cases, hydrophobic parameter of substituents has been found to be a dominant factor. The results of this study led to discuss the selectivity of the compounds for MMP-13 over MMP-1.
Keywords: Quantitative structure-activity relationship, matrix metalloproteinase inhibitors, pyranyl hydroxamic acid analogs
Medicinal Chemistry
Title: A Quantitative Structure-Activity Relationship Study on Some Novel Series of Hydroxamic Acid Analogs Acting as Matrix Metalloproteinase Inhibitors
Volume: 3 Issue: 2
Author(s): S. Kumaran and S. P. Gupta
Affiliation:
Keywords: Quantitative structure-activity relationship, matrix metalloproteinase inhibitors, pyranyl hydroxamic acid analogs
Abstract: A quantitative structure-activity relationship study has been made on some pyranyl hydroxamic acid analogs acting as matrix metalloproteinase (MMP) inhibitors. The inhibition potencies of two different series of compounds against two MMP enzymes (MMP-1 and MMP-13) have been analyzed and found to be well correlated with hydrophobic and some indicator parameters of the substituents. In both the cases, hydrophobic parameter of substituents has been found to be a dominant factor. The results of this study led to discuss the selectivity of the compounds for MMP-13 over MMP-1.
Export Options
About this article
Cite this article as:
Kumaran S. and Gupta P. S., A Quantitative Structure-Activity Relationship Study on Some Novel Series of Hydroxamic Acid Analogs Acting as Matrix Metalloproteinase Inhibitors, Medicinal Chemistry 2007; 3 (2) . https://dx.doi.org/10.2174/157340607780059477
DOI https://dx.doi.org/10.2174/157340607780059477 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Comprehensive Profiling of Protein Ubiquitination for Drug Discovery
Current Pharmaceutical Design Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences CYLD-Mediated Signaling and Diseases
Current Drug Targets Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease
Current Hypertension Reviews Treatment and Response to Statins: Gender-related Differences
Current Medicinal Chemistry Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Induced Pluripotent Stem Cells as a Model for Therapy Personalization of Pediatric Patients: Disease Modeling and Drug Adverse Effects Prevention
Current Medicinal Chemistry Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Editorial (Thematic Issue: Recent Advances in Management of Myocarditis)
Current Pharmaceutical Design A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer s Disease, in Healthy Subjects and Patients
Current Clinical Pharmacology Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART
Current HIV Research Cardiovascular Disease and Inflammation: Novel Biomarkers of Inflammation and Endothelial Activation
Vascular Disease Prevention (Discontinued) The Neurophysiology of Hydrogen Sulfide
Inflammation & Allergy - Drug Targets (Discontinued)